On September 29, 2025, Metsera (acquired by Pfizer) announced positive results from two weight loss phase 1b studies (VESPER-1 and VESPER-13) of MET-097i.
1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-008
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Semaglutide, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
MET-097i is a pioneering fully biased, ultra long acting GLP-1 receptor agonist (GLP-1 RA) with the potential for monthly injection.
The VESPER-1 study (n=239) evaluated the efficacy and safety of MET-0971 (0.4mg-1.2mg, once a week) for 28 weeks without titration. We are currently conducting research expansion and evaluating the effectiveness of lower injection frequencies. The VESPER-3 study is an ongoing clinical trial involving 268 overweight or obese subjects, aimed at evaluating the efficacy and tolerability of MET-097 multiple times a month, and assessing the tolerability of multiple dose escalation strategies during a 12 week midterm analysis. The study lasted for 28 weeks.
In the VESPER-1 study, the average weight loss of the 0.4mg, 0.6mg, 0.9mg, and 1.2mg dose groups after placebo adjustment was -8.1%, -10.0%, -13.0%, and -14.1%, respectively. In addition, the maximum weight loss of individuals in the 1.2mg dose group reached -26.5%. VESPER-3 research is currently underway and there is no weight loss data available for sharing.
MET-097 showed potential class leading tolerability in both studies. In the VESPER-1 study, the tolerance characteristics of high-dose and non titrated MET-097i were similar to those of marketed drugs that require multiple titrations, with a dose-dependent risk difference range of 4% -23% for nausea, 4% -15% for vomiting, and 0% -13% for diarrhea. The 1.2mg dose group, which underwent two-step titration, had the lowest risk of diarrhea in the VESPER-3 study.
Radiolink Technology announces completion of $77 million financing to accelerate global development of radiopharmaceutical pipelines and construction of production facilities in Belgium
On September 30, 2025, Chengdu, China/Belgium Jimbros Radiolink Technology Co., Ltd. (hereinafter referred to as "Radiolink Technology"), a fully integrated clinical stage international radiopharmaceutical therapy company, announced today the completion of a $77 million financing, including approximately $50 million in Series C equity financing and $27 million in debt financing. This round of financing will be used to advance the research and development of the company's global radiopharmaceutical pipeline and the construction of production facilities in Belgium. With the completion of this financing, Fulian Technology has accumulated nearly $200 million in financing since its establishment in 2021, including equity financing, debt financing, and BD transaction payments.
This round of equity financing is led by Jiachen Capital, with multiple high-quality institutions including Longpan Investment, Plaisance, and Zhenmai Investment as co investors. Existing shareholders include Capital, Geding Venture Capital, Sequoia China Prosperity7, Xia Yan Capital and several other institutions continue to invest. In addition to the Series C equity financing, the company has also successfully obtained approximately $27 million in debt financing as flexible funding support, which will provide additional funding solutions for the company's clinical pipeline development and early preclinical project exploration, while ensuring the smooth completion of the Belgian production base.
About Radiance Technology
Fulian Technology Co., Ltd. ("Fulian Technology") is a fully integrated international radiopharmaceutical therapy company in the clinical stage, with offices in Belgium, Germany, and China. Radiolink Technology focuses on global patients and is committed to building a full industry chain nuclear drug company that integrates the research and development, production, and commercialization of radiopharmaceuticals. Through leading innovative research, it solves the fundamental challenges faced by radiopharmaceuticals today and promotes the development of future therapies. The Radiolink Technology team is composed of an efficient team of entrepreneurs and experienced scientists with rich experience in life sciences, radioisotope research, and clinical development.
Small molecule GLP-1 initiates Phase III clinical trials of stress urinary incontinence
The Phase III clinical trial plans to enroll 1000 subjects and is expected to be completed by March 2028.
Orforglipron has achieved success in the phase III clinical trials of diabetes and obesity, and is about to submit an application for listing as the world's first small molecule GLP-1 receptor agonist.
Orforgipron is a small molecule (non peptide) glucagon like peptide-1 receptor agonist (GLP-1 RA) that is currently under development and administered orally once a day. This medication can be taken at any time of the day without restrictions on diet and water. This drug was discovered by Chugai Pharmaceutical Co., Ltd. and authorized for development by Eli Lilly in 2018.